Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333074 | 0.86 | CYP3A4 (0.39) | PLA2G2APLA2G5FASNCYP3A4MAPT | |
| SCHEMBL28515597 | 0.79 | ALDH1A1 (0.44) | MAPTMEN1KMT2A | |
| SCHEMBL22490895 | 0.78 | MEN1 (0.37) | PGK1PGK2FASNMEN1KMT2A | |
| SCHEMBL9720603 | 0.76 | KMT2A (0.50) | PLA2G2APLA2G5PGK1PGK2FASN | |
| SCHEMBL9352415 | 0.75 | KMT2A (0.50) | IMPDH2MEN1KMT2A | |
| SCHEMBL11364813 | 0.74 | GSK3B (0.43) | PGK1PGK2FASN | |
| SCHEMBL11360578 | 0.74 | GSK3B (0.42) | MAPTKMT2A | |
| SCHEMBL5996573 | 0.71 | FASN (0.37) | PLA2G2APLA2G5PGK1PGK2FASN | |
| SCHEMBL1108450 | 0.69 | KMT2A (0.51) | CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL11553322 | 0.68 | CYP3A4 (0.57) | FASNCYP3A4MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137820-A1 | PHOSPHORESCENT aNHC-BASED PLATINUM (II) COMPLEXES | Technische Universität Dresden (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137820-A1 | PHOSPHORESCENT aNHC-BASED PLATINUM (II) COMPLEXES | NDC1, ORC3, NUDC | PLA2G2A 1035/4885PLA2G5 1561/4885PGK1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.